Classification of the frequency of development of side effects of the World Health Organization (WHO):
very often ≥1 / 10
often from ≥1 / 100 to <1/10
infrequently from ≥ 1/1000 to <1/100
rarely from ≥1 / 10000 to <1/1000
very rarely <1/10000
the frequency of the unknown can not be estimated from the available data.
In clinical trials, the overall incidence of adverse reactions did not differ with memantine and placebo. As a rule, they were from mild to moderate severity. The most common adverse reactions in the memantine group compared with placebo were: dizziness (6.3% versus 5.6%, respectively), headache (5.2% vs. 3.9%), constipation (4.6% vs. 2 , 6%), drowsiness (3.4% vs. 2.2%, respectively) and hypertension (4.1% vs. 2.8%, respectively).
Side effects are presented in the form of a table according to the MedDRA classification:
Infectious and parasitic diseases | Rarely | Fungal infections |
Violations of the blood and lymphatic system | Frequency unknown | Agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia, thrombocytopenic purpura |
Immune system disorders | Often | Hypersensitivity to the drug components |
Disorders of the psyche | Often | Drowsiness |
Infrequently | Confusion of consciousness Hallucinations1 |
Frequency unknown | Psychotic reactions |
Disturbances from the nervous system | Often | Dizziness, imbalance |
Infrequently | Violation of gait |
Rarely | Convulsions |
Heart Disease | Infrequently | Heart failure |
Vascular disorders | Often | Increased blood pressure |
Infrequently | Venous thrombosis / thromboembolism |
Disturbances from the respiratory system, chest and mediastinal organs | Often | Dyspnea |
Disorders from the gastrointestinal tract | Often | Constipation |
Infrequently | Nausea, vomiting |
Frequency unknown | Pancreatitis |
Disturbances from the liver and bile ducts | Often | Increased activity of "liver" enzymes |
Frequency unknown | Hepatitis |
Disorders from the kidneys and urinary tract | Frequency unknown | Acute kidney failure |
Disturbances from the skin and subcutaneous tissues | Frequency unknown | Stevens-Johnson Syndrome |
General disorders and disorders at the site of administration | Often | Headache |
Infrequently | Fatigability |
1Hallucinations were observed, mainly, in patients with Alzheimer's disease at the stage of severe dementia. Post-marketing application reported the occurrence of the following adverse reactions: dizziness, drowsiness, increased excitability, increased fatigue, anxiety, increased intracranial pressure, nausea, hallucinations, headache, impairmente consciousness, muscular giPertonus, gait disturbance, depression, convulsions, psychotic reactions, suicidal thoughts, constipation, nausea, pancreatitis, candidiasis, increased blood pressure, vomiting, cystitis, increased libido, venous thrombosis, thromboembolism and allergic reactions.